Keiro Shirotani

Keiro Shirotani

Auto-generated profile, based on publicly available information

Keiro Shirotani

Department of Genome‐based Drug Discovery, Graduate School of Biomedical Sciences Nagasaki University Nagasaki Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKeiro Shirotani
Keiro Shirotani
YHYuma Hori
Yuma Hori
RYRyohei Yoshizaki
Ryohei Yoshizaki
EHEri Higuchi
Eri Higuchi
MCMarco Colonna
Marco Colonna
NINobuhisa Iwata
Nobuhisa Iwata
Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer’s disease, as well as other neurodegenerative disorders. Using a newly developed, highly sensitive reporter cell model, consisting of Jurkat T cells stably overexpressing a reporter gene and a gene encoding TREM2DAP12 fusion protein, we show here that TREM2-dependent signal transduction in response to apoptotic Neuro2a cells is mediated by aminophospholipid ligands, phosphatidylserine and phosphatidylethanolamine, which are not exposed on the intact cell surface, but become exposed upon apoptosis. We also show that signal-transducing TREM2 ligands different from aminophospholipids, which appear to be derived from neurons, might be present in membrane fractions of mouse cerebral cortex. These results may suggest that TREM2 regulates microglial function by transducing intracellular signals from aminophospholipids on apoptotic cells, as well as unidentified ligands in the membranes of the cerebral cortex.

12 September 2022 in The Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
KSKeiro Shirotani
Keiro Shirotani
DHDaisuke Hatta
Daisuke Hatta
NWNaoki Wakita
Naoki Wakita
KWKaori Watanabe
Kaori Watanabe
NINobuhisa Iwata
Nobuhisa Iwata
Variants of triggering receptor expressed on myeloid cells 2 (TREM2) are associated with an increased incidence of Alzheimer’s disease, as well as other neurodegenerative disorders. TREM2 is glycosylated in vitro and in vivo, but the significance of the modification is unknown. We previously established a sensitive and specific reporter cell model involving cultured Jurkat cells stably expressing a luciferase reporter gene and a gene encoding a TREM2DAP12 fusion protein to monitor TREM2-dependent signalling. In the present study, we prepared modified reporter cells to investigate the role of the N-glycans at N20 and N79. We show that the N-glycans at N79 have a requisite role in translocation of TREM2 to the cell surface, while the N-glycans at both N20 and N79 have a critical role in intracellular signal transduction. Our results indicate that structural changes to the TREM2 N-glycans may cause microglial dysfunction that contributes to the pathogenesis of neurodegenerative disorders, and that maintaining the integrity of TREM2 N-glycosylation and the responsible glycosyltransferases may be a novel therapeutic strategy to treat these disorders.

1 July 1992 in Journal of Immunotherapy
Verified
Journal Article
Closed access
MHMasahiro Higuchi
Masahiro Higuchi
KSKeiro Shirotani
Keiro Shirotani
NHNobuaki Higashi
Nobuaki Higashi
STSatoshi Toyoshima
Satoshi Toyoshima
TOToshiaki Osawa
Toshiaki Osawa
Tumor necrosis factor (TNF) has been shown to be cytotoxic to tumor cell lines in vitro, but the mechanism by which TNF exerts its cell growth-regulatory effects is not known. In this report, we used various inhibitors to investigate the sequence of events that lead to cytotoxic effects of TNF on L.P3 cells, a highly sensitive, murine fibroblast cell line. Our results indicate that mitochondrial respiration chains are damaged by a hydroxyl radical at an early stage of the cell lysis after TNF treatment. This event is followed by the activation of phospholipase A2, and finally leads to cell lysis.

4 September 2017 in The Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
KSKeiro Shirotani
Keiro Shirotani
KMKazuya Matsuo
Kazuya Matsuo
SOSumio Ohtsuki
Sumio Ohtsuki
TMTakeshi Masuda
Takeshi Masuda
MAMasashi Asai
Masashi Asai
NINobuhisa Iwata
Nobuhisa Iwata
We developed a simplified and sensitive method to identify Alzheimer’s disease (AD) biomarker candidates by a quantitative and targeted proteomic analysis (combination of liquid chromatography tandem mass spectrometry and multiplexed-multiple reaction monitoring/selected reaction monitoring analysis) of culture media from neurons differentiated from induced pluripotent stem cells (iPSCs) established from AD patients. We found that alpha-1-acid glycoprotein (ORM1) was decreased in the culture media of AD-iPSC–derived neurons, consistent with previous observations for AD patient cerebrospinal fluid, thus validating our new strategy. Moreover, our method is applicable for identifying biomarker candidates for other neurodegenerative disorders using patient-derived iPSCs.

14 February 2023 in Genes to Cells
Verified
Journal Article
Closed access
KSKeiro Shirotani
Keiro Shirotani
KWKaori Watanabe
Kaori Watanabe
DHDaisuke Hatta
Daisuke Hatta
YKYumiko Kutoku
Yumiko Kutoku
YOYutaka Ohsawa
Yutaka Ohsawa
NINobuhisa Iwata
Nobuhisa Iwata

30 September 2024 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
NINobuhisa Iwata
Nobuhisa Iwata
STSatoshi Tsubuki
Satoshi Tsubuki
MSMisaki Sekiguchi
Misaki Sekiguchi
KWKaori Watanabe-Iwata
Kaori Watanabe-Iwata
YMYukio Matsuba
Yukio Matsuba
TSTakaomi C Saido
Takaomi C Saido
The amyloid β peptide (Aβ), starting with pyroglutamate (pE) at position 3 and ending at position 42 (Aβ3pE-42), predominantly accumulates in the brains of Alzheimer’s disease. Consistently, donanemab, a therapeutic antibody raised against Aβ3pE-42, has been shown to be effective in recent clinical trials. Although the primary Aβ produced physiologically is Aβ1-40/42, an explanation for how and why this physiological Aβ is converted to the pathological form remains elusive. Here, we present experimental evidence that accounts for the aging-associated Aβ3pE-42 deposition: Aβ3pE-42 was metabolically more stable than other Aβx-42 variants; deficiency of neprilysin, the major Aβ-degrading enzyme, induced a relatively selective deposition of Aβ3pE-42 in both APP transgenic andAppknock-in mouse brains; Aβ3pE-42 deposition always colocalized with Pittsburgh compound B–positive cored plaques in APP transgenic mouse brains; and under aberrant conditions, such as a significant reduction in neprilysin activity, aminopeptidases, dipeptidyl peptidases, and glutaminyl-peptide cyclotransferase-like were up-regulated in the progression of aging, and a proportion of Aβ1-42 may be processed to Aβ3pE-42. Our findings suggest that anti-Aβ therapies are more effective if given before Aβ3pE-42 deposition.